The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-α and essential for the antiproliferative activity of ICI 182,780 in ERα-positive breast cancer cells

Molecular Endocrinology

Volumn 17, Issue 3, 2003, Pages 356-365

  Fan, Meiyun ^a   Bigsby, Robert M ^b,c   Nephew, Kenneth P ^a,b,c  

^a Indiana University School of Medicine   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; LIGAND; NEDD8 PROTEIN; POLYUBIQUITIN; PROTEASOME; PROTEIN; STEROID RECEPTOR; TRANSCRIPTION FACTOR; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; DRUG ACTIVITY; HORMONE BINDING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PROCESSING; TRANSCRIPTION INITIATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL DIVISION; CYSTEINE ENDOPEPTIDASES; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; IMMUNOBLOTTING; MULTIENZYME COMPLEXES; NEOPLASMS, HORMONE-DEPENDENT; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTORS, ESTROGEN; TRANS-ACTIVATION (GENETICS); TRANSFECTION; TUMOR CELLS, CULTURED; UBIQUITINS;

EID: 0037339988     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2002-0323     Document Type: Article

References (62)

1. McKenna NJ, O'Malley BW 2001 Nuclear receptors, coregulators, ligands, and selective receptor modulators: making sense of the patchwork quilt. Ann NY Acad Sci 949:3-5
2. Webb P, Lopez GN, Greene GL, Baxter JD, Kushner PJ 1992 The limits of the cellular capacity to mediate an estrogen response. Mol Endocrinol 6:157-167
3. Dauvois S, Danielian PS, White R, Parker MG 1992 Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 89:4037-4041
4. Eckert RL, Mullick A, Rorke EA, Katzenellenbogen BS 1984 Estrogen receptor synthesis and turnover in MCF-7 breast cancer cells measured by a density shift technique. Endocrinology 114:629-637
5. Dennis AP, Haq RU, Nawaz Z 2001 Importance of the regulation of nuclear receptor degradation. Front Biosci 6:D954-D959
6. Pickart CM 2001 Mechanisms underlying ubiquitination. Annu Rev Biochem 70:503-533
7. Deshaies RJ 1999 SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 15:435-467
8. Gong L, Yeh ET 1999 Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway. J Biol Chem 274:12036-12042
9. Wada H, Yeh ET, Kamitani T 1999 Identification of NEDD8-conjugation site in human cullin-2. Biochem Biophys Res Commun 257:100-105
10. Hori T, Osaka F, Chiba T, Miyamoto C, Okabayashi K, Shimbara N, Kato S, Tanaka K 1999 Covalent modification of all members of human cullin family proteins by NEDD8. Oncogene 18:6829-6834
11. Lammer D, Mathias N, Laplaza JM, Jiang W, Liu Y, Callis J, Goebl M, Estelle M 1998 Modification of yeast Cdc53p by the ubiquitin-related protein rub1 p affects function of the SCFCdc4 complex. Genes Dev 12:914-926
12. Liakopoulos D, Busgen T, Brychzy A, Jentsch S, Pause A 1999 Conjugation of the ubiquitin-like protein NEDD8 to cullin-2 is linked to von Hippel-Lindau tumor suppressor function. Proc Natl Acad Sci USA 96:5510-5515
13. del Pozo JC, Estelle M 1999 The Arabidopsis cullin At-CUL1 is modified by the ubiquitin-related protein RUB1. Proc Natl Acad Sci USA 96:15342-15347
14. Morimoto M, Nishida T, Honda R, Yasuda H 2000 Modification of cullin-1 by ubiquitin-like protein Nedd8 enhances the activity of SCF(skp2) toward p27(kip1). Biochem Biophys Res Commun 270:1093-1096
15. Podust VN, Brownell JE, Gladysheva TB, Luo RS, Wang C, Coggins MB, Pierce JW, Lightcap ES, Chau V Luo RS, Wang C, Coggins MB, Pierce JW, Lightcap ES, Chau V 2000 A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. Proc Natl Acad Sci USA 97:4579-4584
16. Read MA, Brownell JE, Gladysheva TB, Hottelet M, Parent LA, Coggins MB, Pierce JW, Podust VN, Luo RS, Chau V, Palombella VJ 2000 Nedd8 modification of cul-1 activates SCF(β(TrCP))-dependent ubiquitination of IκBα. Mol Cell Biol 20:2326-2333
17. Ohh M, Kim WY, Moslehi JJ, Chen Y, Chau V, Read MA, Kaelin Jr WG 2002 An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells. EMBO Rep 3:177-182
18. Amir RE, Iwai K, Ciechanover A 2002 The NEDD8 pathway is essential for SCF(β-TrCP)-mediated ubiquitination and processing of the NF-κ B precursor p105. J Biol Chem 277:23253-23259
19. Yang X, Menon S, Lykke-Andersen K, Tsuge T, Di X, Wang X, Rodriguez-Suarez RJ, Zhang H, Wei N 2002 The COP9 signalosome inhibits p27(kip1) degradation and impedes G1-S phase progression via deneddylation of SCF Cul1. Curr Biol 12:667-672
20. Lyapina S, Cope G, Shevchenko A, Serino G, Tsuge T, Zhou C, Wolf DA, Wei N, Deshaies RJ 2001 Promotion of NEDD-CUL1 conjugate cleavage by COP9 signalosome. Science 292:1382-1385
21. Schwechheimer C, Serino G, Callis J, Crosby WL, Lyapina S, Deshaies RJ, Gray WM, Estelle M, Deng XW 2001 Interactions of the COP9 signalosome with the E3 ubiquitin ligase SCFTIRI in mediating auxin response. Science 292:1379-1382
22. Kito K, Yeh ET, Kamitani T 2001 NUB1, a NEDD8-interacting protein, is induced by interferon and down-regulates the NEDD8 expression. J Biol Chem 276:20603-20609
23. Kamitani T, Kito K, Fukuda-Kamitani T, Yeh ET 2001 Targeting of NEDD8 and its conjugates for proteasomal degradation by NUB1. J Biol Chem 276:46655-46660
24. Zhou C, Seibert V, Geyer R, Rhee E, Lyapina S, Cope G, Deshaies RJ, Wolf DA 2001 The fission yeast COP9/ signalosome is involved in cullin modification by ubiquitin-related Ned8p. BMC Biochem 2:7 (http://www.biomedcentral.com/1471-2091/2/7)
25. Fan M, Long X, Bailey JA, Reed CA, Osborne E, Gize EA, Kirk EA, Bigsby RM, Nephew KP 2002 The activating enzyme of NEDD8 inhibits steroid receptor function. Mol Endocrinol 16:315-330
26. Alarid ET, Bakopoulos N, Solodin N 1999 Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. Mol Endocrinol 13:1522-1534
27. Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW 1999 Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA 96:1858-1862
28. Lonard DM, Nawaz Z, Smith CL, O'Malley BW 2000 The 26S proteasome is required for estrogen receptor-α and coactivator turnover and for efficient estrogen receptor-α transactivation. Mol Cell 5:939-948
29. El Khissiin A, Leclercq G 1999 Implication of proteasome in estrogen receptor degradation. FEBS Lett 448:160-166
30. Wijayaratne AL, McDonnell DP 2001 The human estrogen receptor-α is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 276:35684-35692
31. Wada H, Yeh ET, Kamitani T 2000 A dominant-negative UBC12 mutant sequesters NEDD8 and inhibits NEDD8 conjugation in vivo. J Biol Chem 275:17008-17015
32. Chen Y, McPhie DL, Hirschberg J, Neve RL 2000 The amyloid precursor protein-binding protein APP-BP1 drives the cell cycle through the S-M checkpoint and causes apoptosis in neurons. J Biol Chem 275:8929-8935
33. Brooks SC, Locke ER, Soule HD 1973 Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. J Biol Chem 248:6251-6253
34. Levenson AS, Jordan VC 1997 MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res 57:3071-3078
35. Nephew KP, Long X, Osborne E, Burke KA, Ahluwalia A, Bigsby RM 2000 Effect of estradiol on estrogen receptor expression in rat uterine cell types. Biol Reprod 62:168-177
36. Pink JJ, Jordan VC 1996 Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer. cell lines. Cancer Res 56:2321-2330
37. Lippman M, Bolan G, Huff K 1976 The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36:4595-4601
38. Howell A, Osborne CK, Morris C, Wakeling AE 2000 ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer 89:817-825
39. Yeh ET, Gong L, Kamitani T 2000 Ubiquitin-like proteins: new wines in new bottles. Gene 248:1-14
40. Antenos M, Casper RF, Brown TJ 2002 Interaction with NEDD8, a ubiquitin-like protein, enhances the transcriptional activity of the aryl hydrocarbon receptor. J Biol Chem 277:44028-44034
41. Kaul S, Blackford Jr JA, Cho S, Simons Jr SS 2002 Ubc9 is a novel modulator of the induction properties of glucocorticoid receptors. J Biol Chem 277:12541-12549
42. Kotaja N, Aittomaki S, Silvennoinen O, Palvimo JJ, Janne OA 2000 ARIP3 (androgen receptor-interacting protein 3) and other PIAS (protein inhibitor of activated STAT) proteins differ in their ability to modulate steroid receptor-dependent transcriptional activation. Mol Endocrinol 14:1986-2000
43. Poukka H, Aarnisalo P, Karvonen U, Palvimo JJ, Janne OA 1999 Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription. J Biol Chem 274:19441-19446
44. Poukka H, Karvonen U, Janne OA, Palvimo JJ 2000 Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc Natl Acad Sci USA 97:14145-14150
45. Kawakami T, Chiba T, Suzuki T, Iwai K, Yamanaka K, Minato N, Suzuki H, Shimbara N, Hidaka Y, Osaka F, Omata M, Tanaka K 2001 NEDD8 recruits E2-ubiquitin to SCF E3 ligase. EMBO J 20:4003-4012
46. Osaka F, Saeki M, Katayama S, Aida N, Toh EA, Kominami K, Toda T, Suzuki T, Chiba T, Tanaka K, Kato S 2000 Covalent modifier NEDD8 is essential for SCF ubiquitin-ligase in fission yeast. EMBO J 19:3475-3484
47. Wu K, Chen A, Pan ZQ 2000 Conjugation of Nedd8 to CUL1 enhances the ability of the ROC1-CUL1 complex to promote ubiquitin polymerization. J Biol Chem 275:32317-32324
48. Nirmala PB, Thampan RV 1995 Ubiquitination of the rat uterine estrogen receptor: dependence on estradiol. Biochem Biophys Res Commun 213:24-31
49. Stenoien DL, Patel K, Mancini MG, Dutertre M, Smith CL, O'Malley BW, Mancini MA 2001 FRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasome-dependent. Nat Cell Biol 3:15-23
50. Stenoien DL, Cummings CJ, Adams HP, Mancini MG, Patel K, DeMartino GN, Marcelli M, Weigel NL, Mancini MA 1999 Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum Mol Genet 8:731-741
51. Lange CA, Shen T, Horwitz KB 2000 Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci USA 97:1032-1037
52. Okino ST, Whitlock Jr JP 2000 The aromatic hydrocarbon receptor, transcription, and endocrine aspects of dioxin action. Vitam Horm 59:241-264
53. Sheflin L, Keegan B, Zhang W, Spaulding SW 2000 Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels. Biochem Biophys Res Commun 276:144-150
54. Howell A, DeFriend DJ, Robertson JF, Blamey RW, Anderson L, Anderson E, Sutcliffe FA, Walton P 1996 Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 74:300-308
55. Lykkesfeldt AE, Larsen SS, Briand P 1995 Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int J Cancer 61:529-534
56. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI 1995 Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87:746-750
57. Dumont JA, Bitonti AJ, Wallace CD, Baumann RJ, Cashman EA, Cross-Doersen DE 1996 Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ 7:351-359
58. Larsen SS, Heiberg I, Lykkesfeldt AE 2001 Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells. Br J Cancer 84:686-690
59. Brunner N, Boysen B, Jirus S, Skaar TC, Holst-Hansen C, Lippman J, Frandsen T, Spang-Thomsen M, Fuqua SA, Clarke R 1997 MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res 57:3486-3493
60. Meehan KL, Holland JW, Dawkins HJ 2002 Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 50:54-63
61. Furukawa M, Zhang Y, McCarville J, Ohta T, Xiong Y 2000 The CUL1 C-terminal sequence and ROC1 are required for efficient nuclear accumulation, NEDD8 modification, and ubiquitin ligase activity of CUL1. Mol Cell Biol 20:8185-8197
62. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR 1988 Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:589-601